Cargando…

Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs

OBJECTIVES: Disease-modifying therapies in development for Huntington’s disease (HD) may require specialised administration and additional resource capacity. We sought to understand current and future capacity for HD management in Canada considering the possible introduction of an intrathecal (IT) d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bénard, Angèle, Chouinard, Sylvain, Leavitt, Blair R, Budd, Nathalie, Wu, Jennifer W, Schoffer, Kerrie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161103/
https://www.ncbi.nlm.nih.gov/pubmed/35649593
http://dx.doi.org/10.1136/bmjopen-2022-062740
_version_ 1784719415839817728
author Bénard, Angèle
Chouinard, Sylvain
Leavitt, Blair R
Budd, Nathalie
Wu, Jennifer W
Schoffer, Kerrie
author_facet Bénard, Angèle
Chouinard, Sylvain
Leavitt, Blair R
Budd, Nathalie
Wu, Jennifer W
Schoffer, Kerrie
author_sort Bénard, Angèle
collection PubMed
description OBJECTIVES: Disease-modifying therapies in development for Huntington’s disease (HD) may require specialised administration and additional resource capacity. We sought to understand current and future capacity for HD management in Canada considering the possible introduction of an intrathecal (IT) disease-modifying treatment (DMT). DESIGN, SETTING AND PARTICIPANTS: Using a case study, mixed methods framework, online surveys followed by semistructured interviews were conducted in late 2020 and early 2021. Neurologists from Canadian HD (n=16) and community (n=11) centres and social workers (n=16) were invited to complete online surveys assessing current HD management and potential capacity to support administration of an IT DMT. OUTCOME MEASURES: Survey responses, anticipated demand and assumed resource requirements were modelled to reveal capacity to treat (ie, % of eligible patients) by centre. Resource bottlenecks and incremental support required (full-time equivalent, FTE) were also determined. RESULTS: Neurologists from 15/16 HD centres and 5/11 community centres, plus 16/16 social workers participated. HD centres manage 94% of patients with HD currently seeking care in Canada, however, only 20% of IT DMT-eligible patients are currently seen by neurologists. One-third of centres have no access to nursing support. The average national incremental nursing, room, neurologist and social worker support required to provide IT DMT to all eligible patients is 0.73, 0.36, 0.30 and 0.21 FTE per HD centre, respectively. At peak demand, current capacity would support the treatment of 6% of IT DMT-eligible patients. If frequency of administration is halved, capacity for IT-DMT administration only increases to 11%. CONCLUSIONS: In Canada, there is little to no capacity to support the administration of an IT DMT for HD. Current inequitable and inadequate resourcing will require solutions that consider regional gaps and patient needs.
format Online
Article
Text
id pubmed-9161103
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91611032022-06-16 Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs Bénard, Angèle Chouinard, Sylvain Leavitt, Blair R Budd, Nathalie Wu, Jennifer W Schoffer, Kerrie BMJ Open Neurology OBJECTIVES: Disease-modifying therapies in development for Huntington’s disease (HD) may require specialised administration and additional resource capacity. We sought to understand current and future capacity for HD management in Canada considering the possible introduction of an intrathecal (IT) disease-modifying treatment (DMT). DESIGN, SETTING AND PARTICIPANTS: Using a case study, mixed methods framework, online surveys followed by semistructured interviews were conducted in late 2020 and early 2021. Neurologists from Canadian HD (n=16) and community (n=11) centres and social workers (n=16) were invited to complete online surveys assessing current HD management and potential capacity to support administration of an IT DMT. OUTCOME MEASURES: Survey responses, anticipated demand and assumed resource requirements were modelled to reveal capacity to treat (ie, % of eligible patients) by centre. Resource bottlenecks and incremental support required (full-time equivalent, FTE) were also determined. RESULTS: Neurologists from 15/16 HD centres and 5/11 community centres, plus 16/16 social workers participated. HD centres manage 94% of patients with HD currently seeking care in Canada, however, only 20% of IT DMT-eligible patients are currently seen by neurologists. One-third of centres have no access to nursing support. The average national incremental nursing, room, neurologist and social worker support required to provide IT DMT to all eligible patients is 0.73, 0.36, 0.30 and 0.21 FTE per HD centre, respectively. At peak demand, current capacity would support the treatment of 6% of IT DMT-eligible patients. If frequency of administration is halved, capacity for IT-DMT administration only increases to 11%. CONCLUSIONS: In Canada, there is little to no capacity to support the administration of an IT DMT for HD. Current inequitable and inadequate resourcing will require solutions that consider regional gaps and patient needs. BMJ Publishing Group 2022-06-01 /pmc/articles/PMC9161103/ /pubmed/35649593 http://dx.doi.org/10.1136/bmjopen-2022-062740 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Neurology
Bénard, Angèle
Chouinard, Sylvain
Leavitt, Blair R
Budd, Nathalie
Wu, Jennifer W
Schoffer, Kerrie
Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
title Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
title_full Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
title_fullStr Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
title_full_unstemmed Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
title_short Canadian healthcare capacity gaps for disease-modifying treatment in Huntington’s disease: a survey of current practice and modelling of future needs
title_sort canadian healthcare capacity gaps for disease-modifying treatment in huntington’s disease: a survey of current practice and modelling of future needs
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161103/
https://www.ncbi.nlm.nih.gov/pubmed/35649593
http://dx.doi.org/10.1136/bmjopen-2022-062740
work_keys_str_mv AT benardangele canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds
AT chouinardsylvain canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds
AT leavittblairr canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds
AT buddnathalie canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds
AT wujenniferw canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds
AT schofferkerrie canadianhealthcarecapacitygapsfordiseasemodifyingtreatmentinhuntingtonsdiseaseasurveyofcurrentpracticeandmodellingoffutureneeds